display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - HR positive
la/mBC - HR-positive - 1st line (L1)
HER inhibitor
HER2 inhibitor
trastuzumab based treatment
trastuzumab plus endocrine therapy SYSUCC-002
TKI anti HER1/EGFR and HER2/neu
lapatinib based treatment
lapatinib plus fulvestrant CALGB 40302
lapatinib plus letrozole EGF30008 ... EGF30008 ...

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons